Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01HJQ
|
|||
Drug Name |
Aminoazetidine derivative 1
|
|||
Synonyms |
PMID26161824-Compound-164
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Patented | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C29H27Cl2F2N3O4
|
|||
Canonical SMILES |
CCOC(=O)CNC(=O)CC(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F
|
|||
InChI |
1S/C29H27Cl2F2N3O4/c1-2-40-28(39)15-34-26(37)14-27(38)36(24-12-22(32)11-23(33)13-24)25-16-35(17-25)29(18-3-7-20(30)8-4-18)19-5-9-21(31)10-6-19/h3-13,25,29H,2,14-17H2,1H3,(H,34,37)
|
|||
InChIKey |
JLIDBGJVXRJCFP-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [1] |
Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
KEGG Pathway | Rap1 signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Retrograde endocannabinoid signaling | ||||
Panther Pathway | Endogenous cannabinoid signaling | |||
Pathway Interaction Database | N-cadherin signaling events | |||
Reactome | Class A/1 (Rhodopsin-like receptors) | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Small Ligand GPCRs | ||||
BDNF signaling pathway | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.